John Cox is EVP Pharmaceutical Oper & Tech at BIOGEN INC. (BIIB). They have made 7 open-market trades across 3 companies since 2010, most recently 2026-09-08.
CIK 0001498428
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $1.4M since 2024, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DYN | SELL · 10b5-1 | 2026-09-08 | 2026-09-08 | $18.88 | $107K | -11.4% | -15.3% | — |
| DYN | SELL · 10b5-1 | 2026-08-13 | 2026-08-17 | $26.28 | $131K | +0.0% | -33.6% | — |
| DYN | SELL · 10b5-1 | 2026-06-16 | 2026-06-17 | $18.33 | $49K | +9.0% | +16.5% | -12.0% |
| DYN | SELL · 10b5-1 | 2026-05-13 | 2026-05-14 | $18.36 | $61K | +1.7% | +5.2% | +46.7% |
| DYN | SELL · 10b5-1 | 2026-03-05 | 2026-03-06 | $14.90 | $41K | +19.8% | +20.2% | +20.5% |
| DYN | SELL · 10b5-1 | 2025-12-05 | 2025-12-05 | $20.72 | $110K | -12.5% | -15.6% | -29.6% |
| DYN | SELL · 10b5-1 | 2025-09-05 | 2025-09-09 | $13.41 | $35K | -0.5% | +11.2% | +68.2% |
| DYN | BUY | 2025-07-14 | 2025-07-15 | $9.11 | $911K | +10.9% | +39.4% | +56.4% |
| DYN | SELL · 10b5-1 | 2025-06-05 | 2025-06-06 | $13.35 | $54K | -29.1% | -46.2% | -12.9% |
| DYN | SELL · 10b5-1 | 2025-03-05 | 2025-03-07 | $11.83 | $48K | +2.1% | -38.4% | +15.1% |
| DYN | BUY | 2024-09-04 | 2024-09-04 | $33.06 | $503K | -0.9% | -6.1% | -18.8% |
| RGEN | SELL | 2020-03-24 | 2020-03-26 | $96.72 | $359K | +9.5% | +33.6% | +28.1% |
| RGEN | SELL | 2020-03-18 | 2020-03-20 | $95.27 | $5.1M | +6.6% | +17.7% | +28.8% |
| RGEN | SELL | 2020-03-04 | 2020-03-05 | $93.39 | $934K | +7.7% | +11.2% | +40.4% |
| RGEN | SELL | 2020-02-24 | 2020-02-26 | $92.78 | $817K | +10.3% | +11.6% | +60.9% |
| BIIB | SELL · 10b5-1 | 2015-03-25 | 2015-03-26 | $449.06 | $5.4M | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2011-11-01 | 2011-11-03 | $114.37 | $249K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2011-04-21 | 2011-04-25 | $100.00 | $435K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2011-04-13 | 2011-04-15 | $80.00 | $2.9M | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2011-04-11 | 2011-04-13 | $78.00 | $538K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2011-03-31 | 2011-04-01 | $73.00 | $207K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL | 2011-03-02 | 2011-03-03 | $70.10 | $283K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2011-02-17 | 2011-02-18 | $67.08 | $124K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2010-11-09 | 2010-11-10 | $62.87 | $49K | -11.0% | -1.9% | -1.9% |
| BIIB | SELL · 10b5-1 | 2010-11-02 | 2010-11-03 | $63.04 | $48K | -11.0% | -1.9% | -1.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.